-
Fintech Focus Roundup For February 20, 2020
Saturday, February 20, 2021 - 8:21am | 1565Read More...Fintech Spotlight: How Morpher Lets You Buy Apple, On A Weekend, With As Little As $1 When typically discussed, blockchain lacks a utility component. That’s what Morpher CEO Martin Fröhler is looking to change. Fröhler is a mathematician, with a background in quantitative finance,...
-
Psychedelics Advocate, Investor Zappy Says 2021 Is 'The Year To Invest In Plant Medicine'
Monday, February 8, 2021 - 8:21am | 925Read More...Get into psychedelics now. That's according to Michael "Zappy" Zapolin, a former Bear Stearns VP turned psychedelics advocate and filmmaker. Zappy's call to invest comes as psychedelics make a continued push towards credibility on the medical, legal and business...
-
Fintech Focus For January 25, 2021
Monday, January 25, 2021 - 12:47am | 3113Read More...Quote To Start The Day: You can't be a real networker unless you’re connected. Source: Michael Gruen One Big Thing In Fintech: Experts say 2021 is poised to see greater adoption and venture capital investment in blockchain technology. That prediction comes as more financial services apps...
-
MindMed Begins First-Ever Clinical Trial On MDMA, LSD Combinations
Wednesday, January 20, 2021 - 10:11am | 471Read More...Mind Medicine (MindMed) Inc (OTC: MMEDF), a medicine biotech company in psychedelics, on Wednesday announced its start of the first-ever clinical trial measuring and evaluating 3,4-methylenedioxymethamphetamine (MDMA) and lysergic acid diethylamide (LSD) combinations in the human body, at the...
-
Is MindMed Creating The Tesla Of Mental Health? Thoughts From CEO JR Rahn, Investor Kevin O'Leary
Thursday, December 10, 2020 - 10:38am | 516Read More...Mind Medicine (OTC: MMEDF) Co-Founder and CEO J.R. Rahn and investor Kevin O’Leary spoke this week at the inaugural Benzinga Global Small Cap Conference. O’Leary on MindMed: O’Leary for long had avoided the cannabis sector, despite getting numerous deals offered to him....
-
Fintech Focus Roundup For November 28, 2020
Friday, November 27, 2020 - 7:21pm | 1747Read More...Metromile To Go Public Via SPAC, Expand Licensing What Happened: In partnership with INSU Acquisition Corp. II, a SPAC sponsored by the insurance-focused Cohen & Company Inc., insurtech Metromile announced it will become a publicly listed company that would trade on the Nasdaq exchange under...
-
How MindMed Uses Tech To Innovate, Deploy Psychedelic Mental Health Therapies
Wednesday, November 25, 2020 - 9:11am | 990Read More...In an exclusive to Benzinga, Mind Medicine (MindMed) Inc (OTC: MMEDF), a leading medicine biotech company in psychedelics, on Tuesday revealed the introduction of a division known as Albert, to help research and develop an integrated platform for delivering psychedelic medicines, experiential...
-
MindMed Spearheads Phase 2 Trial Of LSD, Fending Off Mental Health Affliction, Impact Of COVID-19 Coronavirus
Tuesday, April 14, 2020 - 4:24pm | 568Read More...The COVID-19 coronavirus has prompted mass business closures, leading some economic forecasters to suggest 50 million jobs may be vulnerable to permanent layoffs, a scenario that may fuel the emergence of a mental health catastrophe. In a bid to address the arrival of a national health crisis, Mind...
-
The Psychedelics Bull Run Has Begun With Publicly-Traded MindMed
Thursday, March 5, 2020 - 12:46pm | 1389Read More...I’ve been telling investors for over a year now that when the first psychedelics pure play goes public, it’s going to crush it. And that’s exactly what happened. This week, MindMed (OTC: MMEDF) went public on the NEO exchange, and also in the U.S. with an OTC listing, trading...
